Taipei, July 21 (CNA) Taiwan-based OBI Pharma announced Monday that its phase 2/3 stage clinical trial for a therapy for metastatic breast cancer, designated OBI-822, has met the goal of collecting 342 patients. OBI Pharma Chairman Michael N. Chang said that the OBI-822 project has progressed more smoothly than expected, and the completion of the collection was a major milestone. The company will analyze the data after the last patient completes the treatment process. According to OBI Pharma General Manager Amy Huang, breast cancer is the most common form of cancer among women and the biggest killer of women's health. The five-year survival rate for metastatic breast cancer is only 24.3 percent, Huang said, stressing that developing this first-class immunotherapy can hopefully satisy this unmet medical need. The concept behind OBI-822, Huang said, is to use the human body's immune system to fight cancer with few side effects, unlike chemotherapy and radiation therapy that harm good cells as well as cancerous cells. The company said this multinational clinical test project was designed as a randomized control trial, with 45 medical centers in Taiwan, the United States, South Korea, India and Hong Kong participating. (By Lo Hsiu-wen and Lilian Wu)